Original Article
Oncogene (2006) 25, 1709–1720. doi:10.1038/sj.onc.1209208; published online 7 November 2005
Deregulation of homologous recombination DNA repair in alkylating agent-treated stem cell clones: a possible role in the aetiology of chemotherapy-induced leukaemia
1Department of Biology, Epidemiology and Genetics Unit, University of York, York, North Yorkshire, UK
Correspondence: Dr JM Allan, Department of Biology, Epidemiology and Genetics Unit, University of York, York, North Yorkshire YO10 5DD, UK. E-mail: jim.allan@egu.york.ac.uk
Received 17 May 2005; Revised 12 September 2005; Accepted 29 September 2005; Published online 7 November 2005.
Abstract
Chemotherapeutic regimes involving alkylating agents, such as methylators and crosslinking nitrogen mustards, represent a major risk factor for acute myeloid leukaemia. A high frequency of microsatellite instability and evidence of MSH2 loss in alkylating chemotherapy-related acute myeloid leukaemia (t-AML) suggests that DNA mismatch repair (MMR) dysfunction may be an initiating event in disease evolution. Subsequent accumulation of secondary genetic changes as a result of DNA MMR loss may ultimately lead to the gross chromosomal abnormalities seen in t-AML. Homologous recombination repair (HRR) maintains chromosomal stability by the repair of DNA double-strand breaks, and is therefore a possible target for deregulation in MMR dysfunctional t-AML. In order to test this hypothesis Msh2- proficient and -deficient murine embryonic stem (ES) cells were used to examine the effects of MMR status and methylating agent treatment on cellular expression of DNA double-strand break repair genes. HRR gene expression was significantly deregulated in Msh2 null ES cell clones compared to wild-type clones. Furthermore, some Msh2 null clones expressed high levels of Rad51 specifically, a critical component of HRR. Such Rad51 superexpressing clones were also observed when expression was determined in monocytic myeloid cells differentiated from ES cells. A deregulated HRR phenotype could be partially recapitulated in MMR-competent wild-type cells by treatment with the methylating agent, N-methyl-N-nitrosourea. Furthermore, treatment with melphalan, a leukaemogenic DNA crosslinking chemotherapy nitrogen mustard predicted to elicit HRR, selected against cells with deregulated HRR. These data suggest a t-AML mechanism whereby DNA MMR loss promotes the emergence of HRR gene superexpressing clones, with concomitant chromosomal instability. However, melphalan selection against clones with deregulated HRR suggests that persistence and expansion of unstable clones may require additional genetic alterations that promote cell survival.
Keywords:
therapy-related AML, DNA mismatch repair, homologous recombination repair, alkylating agents, embryonic stem cells, clones
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
REVIEWS
A role for DNA mismatch repair in sensing and responding to fluoropyrimidine damage
Oncogene Review
Mechanisms of therapy-related carcinogenesis
Nature Reviews Cancer Review (01 Dec 2005)
Journal of Investigative Dermatology Review
RESEARCH
Update on C-reactive protein as a risk marker in cardiovascular disease
Kidney International Original Article
Molecular Therapy Original Article
